Robert A. Winn Excellence in Clinical Trials: Clinical Investigator Leadership Award

The Robert A. Winn Excellence in Clinical Trials: Clinical Investigator Leadership Award Powered by Conquer Cancer's EveryGrant, also described as Winn CILA-Onc, is a three-year career and leadership development program for oncology graduates of the Robert A. Winn Career Development Award program. The program is led by the American Society of Clinical Oncology and funded by the Bristol Myers Squibb Foundation, with collaboration from members of the National Cancer Institute's National Clinical Trials Network. Launched in early 2024, the program has a stated goal of training a total of 25 clinical trialists over a seven-year period. Its purpose is to provide eligible Winn CDA graduates with advanced clinical trials knowledge, leadership development, mentorship, and sponsorship to help them succeed as independent clinical researchers, clinical research team members, and leaders. The three-year program provides 30 percent salary support for protected time during the award period and includes leadership training, coaching, mentorship, sponsorship, and professional development. Participants are expected to attend four in-person leadership training sessions at ASCO Headquarters in Alexandria, Virginia, delivered by an executive leadership coach. The program also includes virtual individual and group coaching sessions, support from an ASCO Mentor and Peer Mentor, placement on an NCTN Protocol Development Committee, assignment of a senior NCTN Committee Member as a mentor, and virtual professional development sessions introducing participants to ASCO initiatives, resources, and opportunities. The program also provides support for NCTN cooperative groups and other training-related costs. The source does not state a dollar-denominated award floor, award ceiling, total program funding amount, or applicant matching or cost-sharing requirement. Applicants must be current or immediate past Robert A. Winn Career Development Award Scholars who have completed or will complete their Winn CDA term by January 15, 2027. Applicants must be in good standing in the Winn CDA program, have completed an oncology subspecialty training, and be employed by an institution that is a current and active member of an NCI National Clinical Trials Network. They must also be able to commit at least 30 percent of full-time effort during the award period, with that commitment confirmed through an institutional Letter of Support. Current scholars are considered in good standing when they are at 80 percent required forum participation and are up to date with program deliverables. All Winn CDA program requirements and funding must be completed and expended by January 2027 for participation in Winn CILA-Onc. Scholars who have already fulfilled all Winn CDA program requirements and are considered Winn CDA alumni may also qualify. The program's example schedule spans three years and includes NCTN committee and sponsor assignments, virtual orientation, four leadership sessions at ASCO Headquarters, virtual ASCO activities, meetings with CILA peer mentors or mentees, career conversations with an ASCO Mentor, and virtual group coaching with an executive leadership coach. The third year concludes with a program close-out call and final evaluation. The source specifically notes that this schedule is an example and that program components and activities are subject to change. The award term for Cohort 4 is January 1, 2027 through December 31, 2029. The Full Application must be prepared in accordance with the requirements and instructions in the applicable Request for Applications and submitted electronically through Conquer Cancer's Application Portal. Paper applications and applications submitted by email or fax are not accepted. The supplied source identifies an institutional Letter of Support as necessary to confirm the applicant's commitment of at least 30 percent full-time effort. It also directs applicants to application resources covering grant writing, finding patient research advocates, other helpful resources, and frequently asked questions. The source does not provide the complete application questions, evaluation or scoring criteria, a direct PDF URL for the Request for Applications, or a named individual program contact with an email address or telephone number. For Cohort 4, applications opened April 27, 2026 and were due June 29, 2026 by 11:59 PM ET. Notification is scheduled for September 2026, and the award term runs from January 1, 2027 through December 31, 2029. As of September 7, 2026, the stated application deadline has passed and the opportunity is closed. Although the page identifies multiple numbered cohorts, the supplied source does not explicitly state an annual, biennial, or other recurring application schedule or provide a date for a subsequent application round, so no future cycle is recorded. Questions concerning Winn CDA standing are directed to the Winn CDA team, while application questions are directed to the ASCO Professional Development team, but no email address or telephone number for either team is included in the supplied material.

Verify Winn CDA standing and completion requirements before applying; confirm the employing institution is a current and active NCTN member; document completion of oncology subspecialty training; secure an institutional Letter of Support confirming at least 30% full-time effort; follow the Request for Applications and submit electronically through Conquer Cancer's Application Portal